Q1 Earnings Estimate for CorMedix Issued By Leerink Partnrs

CorMedix Inc. (NASDAQ:CRMD) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of CorMedix in a note issued to investors on Tuesday, March 25th. Leerink Partnrs analyst R. Ruiz expects that the company will earn $0.23 per share for the quarter. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for CorMedix’s current full-year earnings is ($0.32) per share. Leerink Partnrs also issued estimates for CorMedix’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.16 EPS, Q4 2025 earnings at $0.29 EPS, FY2025 earnings at $0.73 EPS, FY2026 earnings at $2.50 EPS, FY2027 earnings at $3.20 EPS and FY2028 earnings at $3.65 EPS.

CorMedix (NASDAQ:CRMD) last posted its quarterly earnings results on Tuesday, March 25th. The company reported $0.22 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.05. The company had revenue of $30.00 million for the quarter, compared to the consensus estimate of $27.46 million. The business’s quarterly revenue was up 29900.0% compared to the same quarter last year.

Other analysts also recently issued reports about the company. D. Boral Capital reissued a “buy” rating and issued a $15.00 target price on shares of CorMedix in a research report on Tuesday. Royal Bank of Canada reissued an “outperform” rating and issued a $12.00 price objective on shares of CorMedix in a report on Wednesday. Needham & Company LLC dropped their price objective on shares of CorMedix from $18.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Leerink Partners started coverage on shares of CorMedix in a research report on Friday, March 7th. They set an “outperform” rating and a $18.00 target price for the company. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $15.14.

CorMedix Stock Up 0.4 %

Shares of CRMD stock opened at $6.74 on Friday. The firm has a market cap of $408.96 million, a P/E ratio of -8.32 and a beta of 1.53. The company has a 50 day moving average of $10.43 and a 200-day moving average of $9.89. CorMedix has a 12-month low of $3.61 and a 12-month high of $13.85.

Institutional Investors Weigh In On CorMedix

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Elliott Investment Management L.P. grew its stake in CorMedix by 85.1% during the fourth quarter. Elliott Investment Management L.P. now owns 2,870,632 shares of the company’s stock valued at $23,252,000 after acquiring an additional 1,320,109 shares in the last quarter. Palisades Investment Partners LLC bought a new position in CorMedix in the 4th quarter valued at $2,949,000. J. Goldman & Co LP grew its position in shares of CorMedix by 221.1% during the 4th quarter. J. Goldman & Co LP now owns 457,320 shares of the company’s stock valued at $3,704,000 after purchasing an additional 314,880 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of CorMedix by 10.1% in the fourth quarter. Vanguard Group Inc. now owns 3,378,191 shares of the company’s stock worth $27,363,000 after purchasing an additional 309,514 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of CorMedix by 685.5% in the third quarter. JPMorgan Chase & Co. now owns 194,108 shares of the company’s stock worth $1,568,000 after buying an additional 169,397 shares in the last quarter. 34.18% of the stock is currently owned by institutional investors.

About CorMedix

CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.